Exact Sciences Corporation Share Price EXAS

$104.94

▲

1.02

(0.98%)

Last updated on March 20, 2026 at 12:00 am IST

$₹

This instrument is not available for trading on the INDmoney app on 20 Mar 2026

Check the interactive Exact Sciences Corporation Stock chart to analyse performance

Exact Sciences Corporation Key Stats

Check Exact Sciences Corporation key stats like market cap, P/E ratio, EPS, Dividend Yield, and more.

Previous Close	$103.92
Open	$104.93
Market Capitalization	$20.0B
Today's Volume	$21.6M
Revenue TTM	$3.2B
EBITDA	$71.5M
Earnings Per Share (EPS)	$-1.1
Profit Margin	-6.4%
Quarterly Earnings Growth YOY	0.0%
Return On Equity TTM	-8.66%

Global Institutional Holdings in Exact Sciences Corporation

Name
Holdings %
Name
Holdings %
FMR Inc
14.20%
Vanguard Group Inc
9.12%
Capital World Investors
8.46%
Wellington Management Company LLP
6.34%
BlackRock Inc
5.53%
Pentwater Capital Management LP
3.80%

Analyst Recommendation on Exact Sciences Corporation Stock

Rating

Trend

Buy

89%Buy

10%Hold

0%Sell

Based on 29 Wall street analysts offering stock ratings for Exact Sciences Corporation(by analysts ranked 0 to 5 stars)

Exact Sciences Corporation Financials

Revenue

Profit

Cash Flow

Annually

Quarterly

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Revenue	$1.5B	↑ 70.19%
Net Income	$-823.6M	↑ 286.51%
Net Profit Margin	-55.22%	↓ 30.9%

	FY21	Y/Y Change
Revenue	$1.8B	↑ 18.49%
Net Income	$-595.6M	↓ 27.68%
Net Profit Margin	-33.71%	↑ 21.51%

	FY22	Y/Y Change
Revenue	$2.1B	↑ 17.95%
Net Income	$-623.5M	↑ 4.68%
Net Profit Margin	-29.91%	↑ 3.8%

	FY23	Y/Y Change
Revenue	$2.5B	↑ 19.93%
Net Income	$-204.1M	↓ 67.26%
Net Profit Margin	-8.17%	↑ 21.74%

	FY24	Y/Y Change
Revenue	$2.8B	↑ 10.37%
Net Income	$-1.0B	↑ 403.97%
Net Profit Margin	-37.29%	↓ 29.12%

	FY25	Y/Y Change
Revenue	$3.2B	↑ 17.69%
Net Income	$-207.9M	↓ 79.79%
Net Profit Margin	-6.4%	↑ 30.89%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Revenue	$708.7M	↑ 1.34%
Net Income	$-38.2M	↑ 141.88%
Net Profit Margin	-5.4%	↓ 3.14%

	Q4 FY24	Q/Q Change
Revenue	$713.4M	↑ 0.67%
Net Income	$-864.6M	↑ 2161.18%
Net Profit Margin	-121.19%	↓ 115.79%

	Q1 FY25	Q/Q Change
Revenue	$706.8M	↓ 0.93%
Net Income	$-101.2M	↓ 88.29%
Net Profit Margin	-14.32%	↑ 106.87%

	Q2 FY25	Q/Q Change
Revenue	$811.1M	↑ 14.76%
Net Income	$-1.2M	↓ 98.83%
Net Profit Margin	-0.15%	↑ 14.17%

	Q3 FY25	Q/Q Change
Revenue	$850.7M	↑ 4.89%
Net Income	$-19.6M	↑ 1553.5%
Net Profit Margin	-2.3%	↓ 2.15%

	Q4 FY25	Q/Q Change
Revenue	$878.4M	↑ 3.25%
Net Income	$-86.0M	↑ 338.68%
Net Profit Margin	-9.79%	↓ 7.49%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Profit	$1.1B	↑ 72.4%

	FY21	Y/Y Change
Profit	$1.3B	↑ 15.06%

	FY22	Y/Y Change
Profit	$1.4B	↑ 8.76%

	FY23	Y/Y Change
Profit	$1.8B	↑ 23.84%

	FY24	Y/Y Change
Profit	$1.9B	↑ 8.88%

	FY25	Y/Y Change
Profit	$2.3B	↑ 17.94%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Profit	$491.5M	↑ 0.65%

	Q4 FY24	Q/Q Change
Profit	$429.2M	↓ 12.67%

	Q1 FY25	Q/Q Change
Profit	$500.5M	↑ 16.62%

	Q2 FY25	Q/Q Change
Profit	$562.5M	↑ 12.37%

	Q3 FY25	Q/Q Change
Profit	$583.9M	↑ 3.82%

	Q4 FY25	Q/Q Change
Profit	$615.8M	↑ 5.46%

FY20

FY21

FY22

FY23

FY24

FY25

	FY20	Y/Y Change
Operating Cash Flow	$136.5M	↓ 222.24%
Investing Cash Flow	$-702.0M	↑ 464.21%
Financing Cash Flow	$1.9B	↑ 642.4%

	FY21	Y/Y Change
Operating Cash Flow	$-102.2M	↓ 174.91%
Investing Cash Flow	$-1.1B	↑ 54.14%
Financing Cash Flow	$8.5M	↓ 99.55%

	FY22	Y/Y Change
Operating Cash Flow	$-223.6M	↑ 118.67%
Investing Cash Flow	$74.1M	↓ 106.84%
Financing Cash Flow	$76.5M	↑ 802.8%

	FY23	Y/Y Change
Operating Cash Flow	$156.1M	↓ 169.83%
Investing Cash Flow	$49.7M	↓ 32.93%
Financing Cash Flow	$159.8M	↑ 108.89%

	FY24	Y/Y Change
Operating Cash Flow	$210.5M	↑ 34.86%
Investing Cash Flow	$-442.2M	↓ 990.02%
Financing Cash Flow	$231.9M	↑ 45.13%

	FY25	Y/Y Change
Operating Cash Flow	$491.4M	↑ 133.42%
Investing Cash Flow	$195.1M	↓ 144.13%
Financing Cash Flow	$-338.1M	↓ 245.81%

Q3 FY24

Q4 FY24

Q1 FY25

Q2 FY25

Q3 FY25

Q4 FY25

	Q3 FY24	Q/Q Change
Operating Cash Flow	$138.7M	↑ 29.57%
Investing Cash Flow	$-81.7M	↓ 44.46%
Financing Cash Flow	$-226.0K	↓ 100.1%

	Q4 FY24	Q/Q Change
Operating Cash Flow	$47.1M	↓ 66.07%
Investing Cash Flow	$-41.9M	↓ 48.76%
Financing Cash Flow	$10.5M	↓ 4745.58%

	Q1 FY25	Q/Q Change
Operating Cash Flow	$30.8M	↓ 34.54%
Investing Cash Flow	$-34.4M	↓ 17.76%
Financing Cash Flow	$-256.2M	↓ 2539.96%

	Q2 FY25	Q/Q Change
Operating Cash Flow	$89.0M	↑ 188.93%
Investing Cash Flow	$224.9M	↓ 753.06%
Financing Cash Flow	$-4.5M	↓ 98.24%

	Q3 FY25	Q/Q Change
Operating Cash Flow	$219.9M	↑ 147.06%
Investing Cash Flow	$-86.5M	↓ 138.44%
Financing Cash Flow	$-1.5M	↓ 66.06%

	Q4 FY25	Q/Q Change
Operating Cash Flow	$151.7M	↓ 31.03%
Investing Cash Flow	$91.1M	↓ 205.39%
Financing Cash Flow	$-75.9M	↑ 4852.55%

About Exact Sciences Corporation

Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. It offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer; Cologuard Plus Tests; Cancerguard Test; and Genetic Testing. The company also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; Oncodetect Test;OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Riskguard Test, a hereditary cancer test to understand their inherited risk of cancer. Its pipeline focus on advancing screening and diagnostic products, including risk assessment, screening and prevention, early disease diagnosis, adjuvant and/or neoadjuvant disease treatment, metastatic disease treatment selection, and recurrence monitoring. The company has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University, as well as Freenome Holdings, Inc. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.

Organization	Exact Sciences Corporation
Employees	7100
CEO	Mr. Kevin T. Conroy J.D.
Industry	Health Technology

Key Management of Exact Sciences Corporation

Name	Title
Mr. Kevin T. Conroy J.D.	Chairman of the Board, President & CEO
Mr. Aaron Bloomer	EVP & CFO
Ms. Sarah Condella	Executive Vice President of Human Resources & Service
Mr. Jacob Orville MBA	Executive VP & GM of Screening
Mr. Brian Baranick	Executive VP & General Manager of Precision Oncology
Dr. Jorge A. Garces Ph.D.	Chief Science Officer
Mr. Nassar Nizami	Chief Information Officer
Derek Leckow	Vice President of Investor Relations
Mr. James Herriott	Senior VP, General Counsel & Secretary
Mr. Graham P. Lidgard Ph.D.	Emeritus Chief Science Officer

Important FAQs about investing in EXAS Stock from India :

What is Exact Sciences Corporation share price today?

Exact Sciences Corporation share price today is $104.94 as on March 20, 2026 at 12:00 am IST at the close of the market. Exact Sciences Corporation share today touched a day high of {{1_rba_end}} and a low of {{1_rba_st}}.

What is the 52 week high and 52 week low for Exact Sciences Corporation share?

Exact Sciences Corporation share touched a 52 week high of {{rba_end}} and a 52 week low of {{rba_st}}. Exact Sciences Corporation stock price today i.e. March 20, 2026 at 12:00 am IST is closed at $104.94, lower by 0.04% versus the 52 week high.

How to invest in Exact Sciences Corporation Stock (EXAS) from India?

Step 1: Open a free US stocks account on INDmoney App and transfer your Rupees into Dollars to your INDmoney US stocks account. For a step by step instruction, check How to Transfer Money to Your US Stocks Account .
Step 2: Search for Exact Sciences Corporation on INDmoney app. Click on Buy button. You can invest as low as $1.5 in Exact Sciences Corporation Shares that will get you 0.0143 shares as per Exact Sciences Corporation share price of $104.94 per share as on March 20, 2026 at 12:00 am IST.

What is the minimum amount required to buy Exact Sciences Corporation Stock (EXAS) from India?

Indian investors can start investing in Exact Sciences Corporation (EXAS) shares with as little as ₹94.42 or $1 (as of June 22, 2026) using the INDmoney app.
For example: If you want to invest $10 or ₹944.20 in Exact Sciences Corporation stock (as per the Rupee-Dollar exchange rate as on June 22, 2026). Based on Exact Sciences Corporation share’s latest price of $104.94 as on March 20, 2026 at 12:00 am IST, you will get 0.0953 shares of Exact Sciences Corporation. Learn more about fractional shares .

What are the returns that Exact Sciences Corporation has given to Indian investors in the last 5 years?

Exact Sciences Corporation stock has given 0.0% share price returns and 27.35% dollar appreciation to an Indian investor in the last 5 years.
Read more about How do Currency Exchange Rates impact your returns on US Stock Investments?

Discover More

Sangamo Therapeutics, Inc.
$0.18
+0.0%
Chain Bridge I
$7.29
+18.92%
Functional Brands, Inc. Common Stock
$0.01
+0.0%
GraniteShares ETF Trust GraniteShares 2x Long ETOR Daily ETF
$12.57
+0.0%
GraniteShares ETF Trust GraniteShares 2x Short MSTR Daily ETF
$47.88
+0.02%
Clear Secure, Inc.
$51.45
+1.34%
Draco Evolution AI ETF
$34.86
+2.38%
T-REX 2X Long SNDK Daily Target ETF
$68.27
+22.61%
Aebi Schmidt Holding AG Common Stock
$12.33
+2.66%

Explore all